These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 24396495)

  • 61. Comparison of tumor-associated trypsin inhibitor (TATI) with CA125 as a marker for diagnosis and monitoring of epithelial ovarian cancer.
    Gadducci A; Ferdeghini M; Rispoli G; Prontera C; Bianchi R; Fioretti P
    Scand J Clin Lab Invest Suppl; 1991; 207():19-24. PubMed ID: 1780685
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Serum CA125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal women.
    Jeyarajah AR; Ind TE; Skates S; Oram DH; Jacobs IJ
    Cancer; 1999 May; 85(9):2068-72. PubMed ID: 10223249
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
    Shi T; Zhu J; Feng Y; Tu D; Zhang Y; Zhang P; Jia H; Huang X; Cai Y; Yin S; Jiang R; Tian W; Gao W; Liu J; Yang H; Cheng X; Zang R
    Lancet Oncol; 2021 Apr; 22(4):439-449. PubMed ID: 33705695
    [TBL] [Abstract][Full Text] [Related]  

  • 65. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use.
    Duffy MJ; Bonfrer JM; Kulpa J; Rustin GJ; Soletormos G; Torre GC; Tuxen MK; Zwirner M
    Int J Gynecol Cancer; 2005; 15(5):679-91. PubMed ID: 16174214
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment.
    Ray-Coquard I; Mirza MR; Pignata S; Walther A; Romero I; du Bois A
    Cancer Treat Rev; 2020 Nov; 90():102107. PubMed ID: 33099187
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
    Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The role of biomarkers in the management of epithelial ovarian cancer.
    Yang WL; Lu Z; Bast RC
    Expert Rev Mol Diagn; 2017 Jun; 17(6):577-591. PubMed ID: 28468520
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Usefulness of (18)F-FDG PET in the post-therapy surveillance of endometrial carcinoma.
    Belhocine T; De Barsy C; Hustinx R; Willems-Foidart J
    Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1132-9. PubMed ID: 12192557
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Advances in the management of epithelial ovarian cancer.
    Berkenblit A; Cannistra SA
    J Reprod Med; 2005 Jun; 50(6):426-38. PubMed ID: 16050567
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Patterns of failure following surgical resection for malignant pleural mesothelioma.
    Jänne PA; Baldini EH
    Thorac Surg Clin; 2004 Nov; 14(4):567-73. PubMed ID: 15559064
    [TBL] [Abstract][Full Text] [Related]  

  • 72. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations.
    Salani R; Khanna N; Frimer M; Bristow RE; Chen LM
    Gynecol Oncol; 2017 Jul; 146(1):3-10. PubMed ID: 28372871
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Serum CA125 and ascites leptin level ratio predicts baseline clinical resistance to first-line platinum-based treatment and poor prognosis in patients with high grade serous ovarian cancer.
    Matte I; Garde-Granger P; Bessette P; Piché A
    Am J Cancer Res; 2019; 9(1):160-170. PubMed ID: 30755819
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Abdominal recurrence of ovarian cancer: value of abdominal MR in patients with positive CA125 and negative CT.
    Balestreri L; Bison L; Sorio R; Morra A; Campagnutta E; Morassut S
    Radiol Med; 2002; 104(5-6):426-36. PubMed ID: 12589264
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Importance of CA125 normalization during neoadjuvant chemotherapy followed by planned delayed surgical debulking in patients with epithelial ovarian cancer.
    Le T; Faught W; Hopkins L; Fung-Kee-Fung M
    J Obstet Gynaecol Can; 2008 Aug; 30(8):665-670. PubMed ID: 18786288
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
    Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer.
    Schorge JO; Drake RD; Lee H; Skates SJ; Rajanbabu R; Miller DS; Kim JH; Cramer DW; Berkowitz RS; Mok SC
    Clin Cancer Res; 2004 May; 10(10):3474-8. PubMed ID: 15161704
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Role of FDG PET-CT in asymptomatic epithelial ovarian cancer with rising serum CA-125: a pilot study.
    Ghosh J; Thulkar S; Kumar R; Malhotra A; Kumar A; Kumar L
    Natl Med J India; 2013; 26(6):327-31. PubMed ID: 25073988
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Revisiting the clinical value of 18F-FDG PET/CT in detection of recurrent epithelial ovarian carcinomas: correlation with histology, serum CA-125 assay, and conventional radiological modalities.
    Antunovic L; Cimitan M; Borsatti E; Baresic T; Sorio R; Giorda G; Steffan A; Balestreri L; Tatta R; Pepe G; Rubello D; Cecchin D; Canzonieri V
    Clin Nucl Med; 2012 Aug; 37(8):e184-8. PubMed ID: 22785525
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The application value of the detection of the level of tissue polypeptide antigen, ovarian cancer antigen X1, cathepsin L and CA125 on the diagnosis of epithelial ovarian cancer.
    Lv XL; Zhu Y; Liu JW; Ai H
    Eur Rev Med Pharmacol Sci; 2016 Dec; 20(24):5113-5116. PubMed ID: 28051260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.